{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:42:15Z","timestamp":1777419735167,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2002,8,30]],"date-time":"2002-08-30T00:00:00Z","timestamp":1030665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,8,30]],"date-time":"2002-08-30T00:00:00Z","timestamp":1030665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2002,9,1]]},"DOI":"10.1038\/sj.leu.2402573","type":"journal-article","created":{"date-parts":[[2002,9,20]],"date-time":"2002-09-20T18:43:46Z","timestamp":1032547426000},"page":"1808-1817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro"],"prefix":"10.1038","volume":"16","author":[{"given":"M","family":"Akutsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,8,30]]},"reference":[{"key":"BF2402573_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/JCO.1989.7.8.1018","volume":"7","author":"B Coiffier","year":"1989","unstructured":"Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N . LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma J Clin Oncol 1989 7: 1018\u20131026","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","volume":"12","author":"MA Schorin","year":"1994","unstructured":"Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE . Treatment of childhood acutelymphoblastic leukemia: results of Dana-Farber Cancer Institute\/Children's Hospital Acute lymphoblastic leukemia Consortium Protocol 85\u201301 J Clin Oncol 1994 12: 740\u2013747","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<511::AID-CNCR33>3.0.CO;2-H","volume":"85","author":"AM Moser","year":"1999","unstructured":"Moser AM, Adamson PC . Intraventricular concentration times time (C \u00d7 T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma Cancer 1999 85: 511\u2013516","journal-title":"Cancer"},{"key":"BF2402573_CR4","first-page":"951","volume":"4","author":"C Porchedly","year":"1990","unstructured":"Porchedly C . Prevention of meningeal leukemia. Review of 20 years of research and current recommendations Hematol Oncol Clin N Am 1990 4: 951\u2013969","journal-title":"Hematol Oncol Clin N Am"},{"key":"BF2402573_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V84.2.355.355","volume":"84","author":"D Pinkel","year":"1994","unstructured":"Pinkel D, Woo S . Prevention and treatment of meningeal leukemia in children Blood 1994 84: 355\u2013366","journal-title":"Blood"},{"key":"BF2402573_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.1991.9.1.25","volume":"9","author":"DL Longo","year":"1991","unstructured":"Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI . Superiority of ProMACE-CytaBOM over ProMACEMOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial J Clin Oncol 1991 9: 25\u201338","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR7","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V94.10.3307.422k11_3307_3314","volume":"94","author":"LI Gordon","year":"1999","unstructured":"Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA . A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity Blood 1999 94: 3307\u20133314","journal-title":"Blood"},{"key":"BF2402573_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.1993.11.2.248","volume":"11","author":"BA Parker","year":"1993","unstructured":"Parker BA, Santarelli M, Green MR, Anderson JR, Cooper MR, Case D Jr, Barcos M, Peterson BA, Gottlieb AJ . AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study J Clin Oncol 1993 11: 248\u2013254","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR9","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO.1998.16.8.2840","volume":"16","author":"MB Harris","year":"1998","unstructured":"Harris MB, Shuster JJ, Jeanette Pullen D, Borowitz MJ, Carroll AJ, Behm FG, Land VJ . Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphoblastic leukemia of childhood: a pediatric oncology group study J Clin Oncol 1998 16: 2840\u20132847","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2001.19.7.1935","volume":"19","author":"F Millot","year":"2001","unstructured":"Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J . Value of high-dose cytarabine during interval therapy of a Berlin\u2013Frankfurt\u2013Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial J Clin Oncol 2001 19: 1935\u20131942","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.1991.9.1.123","volume":"9","author":"C Patte","year":"1991","unstructured":"Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC, Lamagnere JP, Otten J, Dufillot D, Pein F . High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children J Clin Oncol 1991 9: 123\u2013132","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.1996.14.3.945","volume":"14","author":"EM Bessell","year":"1996","unstructured":"Bessell EM, Graus F, Punt JA, Firth JL, Hope DT, Moloney AJ, Lopez Guillermo A, Villa S . Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD\/BVAM chemotherapy before radiotherapy J Clin Oncol 1996 14: 945\u2013954","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.1996.14.4.1252","volume":"14","author":"WP Bowman","year":"1996","unstructured":"Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy STI . Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study J Clin Oncol 1996 14: 1252\u20131261","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O7Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating M, Murphy S, Freireich EJ . Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia J Clin Oncol 2000 18: 547\u2013561","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR15","first-page":"435","volume":"51","author":"JH Burchenal","year":"1967","unstructured":"Burchenal JH, Dollinger MR . Cytosine in combination with 6-mercaptopurine, methotrexate, or 5-fluorouracil in L1210 mouse leukemia Cancer Chemother Rep 1967 51: 435\u2013438","journal-title":"Cancer Chemother Rep"},{"key":"BF2402573_CR16","first-page":"527","volume":"32","author":"G Grindey","year":"1972","unstructured":"Grindey G, Nichol CA . Interaction of drugs inhibiting different steps in the synthesis of DNA Cancer Res 1972 32: 527\u2013531","journal-title":"Cancer Res"},{"key":"BF2402573_CR17","first-page":"521","volume":"33","author":"ML Hoovis","year":"1973","unstructured":"Hoovis ML, Chu MY . Enhancement of the antiproliferative action of 1-b-D-arabinofuranosylcytosine by methotrexate in murine leukemia cells (L5178Y) Cancer Res 1973 33: 521\u2013525","journal-title":"(L5178Y) Cancer Res"},{"key":"BF2402573_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0014-2964(73)80023-4","volume":"9","author":"MH Tattersall","year":"1973","unstructured":"Tattersall MH, Harrap KR . Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside Eur J Cancer 1973 9: 229\u2013232","journal-title":"Eur J Cancer"},{"key":"BF2402573_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0014-2964(74)90025-5","volume":"10","author":"TL Avery","year":"1974","unstructured":"Avery TL, Roberts D . Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210 Eur J Cancer 1974 10: 425\u2013429","journal-title":"Eur J Cancer"},{"key":"BF2402573_CR20","first-page":"1555","volume":"35","author":"M Edelson","year":"1975","unstructured":"Edelson M, Vietti T, Valeriote F . The enhanced cytotoxicity of combinations of 1-b-D-arabinofuranosylcytosine and methotrexate Cancer Res 1975 35: 1555\u20131558","journal-title":"Cancer Res"},{"key":"BF2402573_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1172\/JCI109525","volume":"64","author":"E Cadman","year":"1979","unstructured":"Cadman E, Eiferman F . Mechanism of synergistic cell killing when methotrexate precedes cytarabine: study of L1210 and human leukemia cells J Clin Invest 1979 64: 788\u2013797","journal-title":"J Clin Invest"},{"key":"BF2402573_CR22","first-page":"4048","volume":"39","author":"DW Roberts","year":"1979","unstructured":"Roberts DW, Peck C, Hilliard C, Wingo W . Methotrexcate-induced changes in the levels of 1-b-D-arabinofuranosylcytosine triphosphate in L1210 cells Cancer Res 1979 39: 4048\u20134054","journal-title":"Cancer Res"},{"key":"BF2402573_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0006-2952(81)90082-4","volume":"30","author":"RC Jackson","year":"1981","unstructured":"Jackson RC, Harkrader RJ . Synergistic and antagonistic interactions of methotrexate and 1-b-D-arabinofuranosylcytosine in hepatoma cells: the modulating effect of purines Biochem Pharmacol 1981 30: 223\u2013229","journal-title":"Biochem Pharmacol"},{"key":"BF2402573_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0145-2126(89)90139-2","volume":"13","author":"A Tanizawa","year":"1989","unstructured":"Tanizawa A, Kubota M, Takimoto T, Kito T, Akiyama Y, Kiriyama Y, Mikawa H . Synergistic effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line Leuk Res 1989 13: 151\u2013156","journal-title":"Leuk Res"},{"key":"BF2402573_CR25","first-page":"93","volume":"41","author":"MC Berenbaum","year":"1988","unstructured":"Berenbaum MC . What is synergy? Pharmacol Rev 1988 41: 93\u2013141","journal-title":"Pharmacol Rev"},{"key":"BF2402573_CR26","first-page":"2315","volume":"14","author":"JL Merlim","year":"1994","unstructured":"Merlim JL . Concepts of synergism and antagonism Anticancer Res 1994 14: 2315\u20132320","journal-title":"Anticancer Res"},{"key":"BF2402573_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/B978-1-4831-9929-0.50013-9","volume":"1","author":"JM Vendette","year":"1964","unstructured":"Vendette JM, Goldin A . drug synergism in antineoplastic chemotherapy Adv Chemother 1964 1: 397\u2013498","journal-title":"Adv Chemother"},{"key":"BF2402573_CR28","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S . The problem of synergism and antagonism of combined drugs Arzneim Forsch 1953 3: 285\u2013290","journal-title":"Arzneim Forsch"},{"key":"BF2402573_CR29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5962\/bhl.title.7320","volume-title":"Enzymes and Metabolic Inhibitors","author":"JL Webb","year":"1963","unstructured":"Webb JL . Effect of more than one inhibitor In Enzymes and Metabolic Inhibitors Academic Press: New York 1963 pp 66\u201379"},{"key":"BF2402573_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/jnci\/86.20.1517","volume":"86","author":"TC Chou","year":"1994","unstructured":"Chou TC, Motzer RJ, Tong Y, Bosl GJ . Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design Nat Cancer Inst 1994 86: 1517\u20131524","journal-title":"Nat Cancer Inst"},{"key":"BF2402573_CR31","first-page":"8","volume":"5","author":"GG Steel","year":"1979","unstructured":"Steel GG, Peckham MJ . Exploitable mechanisms in combined radiotherapy\u2013chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 1979 5: 8\u201391","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF2402573_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/59.1.93","volume":"59","author":"S Hiraki","year":"1977","unstructured":"Hiraki S, Miyoshi I, Masuji H, Kubonishi I, Matsuda Y . Establishment of an Epstein\u2013Barr virus-determined nuclear antigen-negative human B-cell line from acute lymphoblastic leukemia J Natl Cancer Inst 1977 59: 93\u201394","journal-title":"J Natl Cancer Inst"},{"key":"BF2402573_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/0145-2126(91)90112-7","volume":"15","author":"Y Kano","year":"1991","unstructured":"Kano Y, Sakamoto S, Kasahara T, Akutsu M, Inoue Y, Miura Y . In vitro effects of amsacrine in combination with other anticancer agents Leukemia Res 1991 15: 1059\u20131064","journal-title":"Leukemia Res"},{"key":"BF2402573_CR34","first-page":"351","volume":"48","author":"Y Kano","year":"1988","unstructured":"Kano Y, Ohnuma T, Okano T, Holland JF . Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture Cancer Res 1988 48: 351\u2013356","journal-title":"Cancer Res"},{"key":"BF2402573_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ijc.2910500420","volume":"50","author":"Y Kano","year":"1992","unstructured":"Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y . Effects of CPT-11 in combination with other anticancer agents in culture Int J Cancer 1992 50: 604\u2013609","journal-title":"Int J Cancer"},{"key":"BF2402573_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s002800050790","volume":"42","author":"Y Kano","year":"1998","unstructured":"Kano Y, Akutsu M, Tsunoda S, Suzuki K, Adachi K . In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines Cancer Chemother Pharmacol 1998 42: 91\u201398","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2402573_CR37","doi-asserted-by":"publisher","first-page":"21661","DOI":"10.1074\/jbc.M906893199","volume":"275","author":"Y Furukawa","year":"2000","unstructured":"Furukawa Y, Iwase S, Kikuchi J, Nakamura M, Terui Y, Yamada H, Kano Y, Matsuda M . Phosphorylation of bcl-2 protein by cdc2 kinase during G2\/M phases and its role in cell cycle regulation J Biol Chem 2000 275: 21661\u201321667","journal-title":"J Biol Chem"},{"key":"BF2402573_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ijc.2910450128","volume":"45","author":"A Lorico","year":"1990","unstructured":"Lorico A, Boiocchi M, Rappa G, Sen S, Erba E, D'Incalci M . Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate Int J Cancer 1990 45: 156\u2013162","journal-title":"Int J Cancer"},{"key":"BF2402573_CR39","first-page":"687","volume":"29","author":"M Karon","year":"1970","unstructured":"Karon M, Chirakawa S . The locus of action of 1-b-D-arabinofuranosylcytosine in the cell cycle Cancer Res 1970 29: 687\u2013694","journal-title":"Cancer Res"},{"key":"BF2402573_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bjc.1998.751","volume":"78 (Suppl. 3)","author":"VJ Chen","year":"1998","unstructured":"Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, Mendelsohn LG, Seitz DE, Tonkinson JL . Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells Br J Cancer 1998 78 (Suppl. 3): 27\u201334","journal-title":"Br J Cancer"},{"key":"BF2402573_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/BF00689278","volume":"27","author":"EM Newman","year":"1990","unstructured":"Newman EM, Villacorte DG, Testi AM, Krance RA, Harris MB, Ravindranath Y, Pinkel D . Biochemical interactions between methotrexate and1-beta-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study Cancer Chemother Pharmacol 1990 27: 60\u201366","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2402573_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0360-3016(92)91020-N","volume":"24","author":"J Giralt","year":"1992","unstructured":"Giralt J, Ortega JJ, Oliwe T, Verges R, Forio I, Salvador L . Long term neuropsychologic sequence of childhood leukemia: comparison of two CNS prophylactic regimens Int J Radiat Oncol Biol Phys 1992 24: 49\u201353","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF2402573_CR43","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","volume":"19","author":"EJ Lee","year":"2001","unstructured":"Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA . Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251 J Clin Oncol 2001 19: 4014\u20134022","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/clpt.1984.120","volume":"35","author":"S Zimm","year":"1984","unstructured":"Zimm S, Collins JM, Miser J, Chatterji D, Poplack D . Cytosine arabinoside cerebrospinal fluid kinetics Clin Pharmacol Ther 1984 35: 826\u2013830","journal-title":"Clin Pharmacol Ther"},{"key":"BF2402573_CR45","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.1989.7.11.1741","volume":"7","author":"DR Strother","year":"1989","unstructured":"Strother DR, Glynn-Barnhart A, Kovnar E, Gregory RE, Murphy SB . Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing J Clin Oncol 1989 7: 1741\u20131747","journal-title":"J Clin Oncol"},{"key":"BF2402573_CR46","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB . A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors Clin Cancer Res 1999 5: 3394\u20133402","journal-title":"Clin Cancer Res"},{"key":"BF2402573_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 1993 328: 1002\u20131006","journal-title":"N Engl J Med"},{"key":"BF2402573_CR48","first-page":"331","volume":"2","author":"ML Graham","year":"1996","unstructured":"Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, Camitta B, Cheo DL, Harrison MP, Leventhal BG, Pinkel DP, Pullen DJ, Steuber P, Whitehead VM . Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphoblastic leukemia in children Clin Cancer Res 1996 2: 331\u2013337","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402573","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T01:49:41Z","timestamp":1704592181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,30]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9,1]]}},"alternative-id":["BF2402573"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402573","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,30]]},"assertion":[{"value":"27 November 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}